Sunhawk Vision Biotech, Inc.

Sunhawk Vision Biotech, Inc. is a biotechnology company specializing in the development of RNA-based therapeutics, with a primary focus on ophthalmic conditions. Founded in 2019 and headquartered in Kaohsiung, Taiwan, the company pioneers the use of a proprietary RNA therapy platform to address diseases such as myopia, dry eye syndrome, and other eye disorders. Its lead product candidate is a microRNA-328 inhibitor, specifically designed as a therapeutic eye drop for controlling and treating pediatric myopia, reflecting an innovative approach in nucleic acid drug development. Sunhawk Vision Biotech leverages advanced oligonucleotide technologies to target unmet medical needs within the broader pharmaceuticals and biotech sector. The company contributes to both local and global efforts in ophthalmic drug research, actively advancing its pipeline through clinical trials and collaborative research initiatives. By focusing on next-generation therapies for vision-related disorders, Sunhawk Vision Biotech holds a distinctive position within the biotechnology industry, driving advancements in nucleic acid-based treatments for ocular health.